<PAGE> 1
SCHEDULE 14A
(RULE 14A-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
Filed by the Registrant [X]
Filed by a Party other than the Registrant
Check the appropriate box:
<TABLE>
<S> <C>
[X] Preliminary Proxy Statement [X] Confidential, For Use of the Commission
Only (as Permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
</TABLE>
Endorex Corp.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, If Other Than Registrant)
Payment of filing fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transactions applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE> 2
ENDOREX CORPORATION LETTERHEAD
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
MAY 13, 1998
TO THE STOCKHOLDERS:
The annual meeting of stockholders (the "Annual Meeting") of
Endorex Corp. (the "Company") will be held at the offices of Brobeck Phleger &
Harrison LLP, 1633 Broadway, 47th Floor, New York, New York 10019, telephone
number (212) 581-1600 on May 13, 1998, at 10:30 A.M. (eastern daylight time) for
the following purposes, each as more fully described herein:
(1) To elect eight directors to serve until the next Annual Meeting or
until their respective successors shall have been duly elected and
qualified;
(2) To ratify the appointment of Coopers & Lybrand L.L.P. as independent
public accountants for the year ending December 31, 1998;
(3) To approve the Amended and Restated 1995 Omnibus Incentive Plan;
(4) To approve name change of the Company from "Endorex Corp." to
"Endorex Corporation"; and
(5) To transact such other business as may properly come before the
Annual Meeting.
Only stockholders of record at the close of business on March 27,
1998 are entitled to notice of and to vote at the Annual Meeting. A list of
stockholders eligible to vote at the meeting will be available for inspection at
the meeting and for a period of ten days prior to the meeting during regular
business hours at the corporate headquarters at the address above.
Whether or not you expect to attend the Annual Meeting, your proxy
vote is important. To assure your representation at the Annual Meeting, please
sign and date the enclosed proxy card and return it promptly in the enclosed
envelope, which requires no additional postage if mailed in the United States.
By Order of the Board of Directors
Michael S. Rosen
Chief Executive Officer and President
Lake Bluff, Illinois
April 10, 1998
- --------------------------------------------------------------------------------
IT IS IMPORTANT THAT THE ENCLOSED PROXY CARD
BE COMPLETED AND RETURNED PROMPTLY
- --------------------------------------------------------------------------------
<PAGE> 3
THIS PAGE INTENTIONALLY LEFT BLANK.
<PAGE> 4
ENDOREX CORP.
PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS
INTRODUCTION
This Proxy Statement is furnished to stockholders of record of
Endorex Corp. (the "Company") as of the close of business on March 27, 1998 in
connection with the solicitation of proxies by the Board of Directors of the
Company (the "Board of Directors" or "Board") for use at the Annual Meeting of
Stockholders to be held on May 13, 1998 (the "Annual Meeting").
Shares cannot be voted at the meeting unless the owner is present
in person or by proxy. All properly executed and unrevoked proxies in the
accompanying form that are received in time for the meeting will be voted at the
meeting or any adjournment thereof in accordance with instructions thereon, or
if no instructions are given, will be voted "FOR" the election of the named
nominees as Directors of the Company, "FOR" the ratification of Coopers &
Lybrand L.L.P. as independent public accountants for the year ending December
31, 1998, "FOR" the approval of the Amended and Restated 1995 Omnibus Incentive
Plan, and "FOR" the approval of the name change to "Endorex Corporation" and
will be voted in accordance with the best judgment of the persons appointed as
proxies with respect to other matters which properly come before the Annual
Meeting. Any person giving a proxy may revoke it by written notice to the
Company at any time prior to exercise of the proxy. In addition, although mere
attendance at the Annual Meeting will not revoke the proxy, a stockholder who
attends the meeting may withdraw his or her proxy and vote in person.
Abstentions and broker non-votes will be counted for purposes of determining the
presence or absence of a quorum for the transaction of business at the Annual
Meeting. Abstentions will be counted in tabulations of the votes cast on each of
the proposals presented at the Annual Meeting, whereas broker non-votes will not
be counted for purposes of determining whether a proposal has been approved.
The Annual Report of the Company (which does not form a part of the
proxy solicitation materials), including the Annual Report on Form 10-KSB (the
"Form 10-KSB") with the financial statements of the Company for the fiscal year
ended December 31, 1997, is being distributed concurrently herewith to
stockholders.
The mailing address of the principal executive offices of the
Company is 900 North Shore Drive, Lake Bluff, IL 60044. This Proxy Statement and
the accompanying form of proxy are being mailed to the stockholders of the
Company on or about April 16, 1998.
VOTING SECURITIES
The Company has two classes of voting securities: Common Stock and
Series B Preferred Stock. At the Annual Meeting, each stockholder of record at
the close of business on March 27, 1998 will be entitled to one vote for each
share of Common Stock owned on that date as to each matter presented at the
Annual Meeting. On March 16, 1998, 9,936,000 shares of Common Stock and 80,100
shares of Preferred Stock representing 1,068,000 shares of Common Stock were
outstanding. A list of stockholders eligible to vote at the Annual Meeting will
be available for inspection at the Annual Meeting and for a period of ten days
prior to the Annual Meeting during regular business hours at the principal
executive offices of the Company at the address specified above.
In June 1997, the Company effected a one-for-fifteen reverse stock
split. All share and per share amounts in this proxy have been adjusted to
effect such reverse stock split.
1
<PAGE> 5
PROPOSAL 1
ELECTION OF DIRECTORS
Unless otherwise directed, the persons appointed in the
accompanying form of proxy intend to vote at the Annual Meeting for the election
of the eight nominees named below as Directors of the Company to serve until the
next Annual Meeting or until their successors are duly elected and qualified. If
any nominee is unable to be a candidate when the election takes place, the
shares represented by valid proxies will be voted in favor of the remaining
nominees. The Board of Directors does not currently anticipate that any nominee
will be unable to be a candidate for election.
The Board of Directors currently has eight members, all of whom are
nominees for re-election. Each director shall serve until the next Annual
Meeting or until their respective successors shall have been duly elected and
qualified. Steve Kanzer, Michael Rosen and Kenneth Tempero were elected to the
Board of Directors by the stockholders at the 1997 annual stockholders meeting.
Richard Dunning and H. Laurence Shaw were appointed by the Board of Directors to
the Board of Directors in August 1997, Paul Rubin was appointed by the Board of
Directors to the Board of Directors in November 1997, Andrew Stein was appointed
by the Board of Directors to the Board of Directors in January 1998, and Steve
Thornton was appointed by the Board of Directors to the Board of Directors in
February 1998.
The affirmative vote of a plurality of the Company's outstanding
Common Stock represented and voting at the Annual Meeting is required to elect
the Directors.
NOMINEES FOR ELECTION AS DIRECTORS
The following information with respect to the principal occupation
or employment, other affiliations and business experience of each nominee during
the last five years has been furnished to the Company by such nominee. Except as
indicated, each of the nominees has had the same principal occupation for the
last five years.
MICHAEL S. ROSEN, M.B.A., 45, has served as President, Chief
Executive Officer and a member of the Board of Directors of the Company since
August 1996. From January 1995 until August 1996, he was President and Chief
Executive Officer of PharmaMar, S.A., a European biotech company. From June 1991
until January 1995, Mr. Rosen was General Manager of the northern Latin American
businesses for Monsanto Company, a multinational chemical/pharmaceutical
company. Mr. Rosen received a B.A. in Sociology/International Relations from
Beloit College and an M.B.A. in International Business from the University of
Miami. He has undertaken post-graduate courses at Northwestern University and
Sophia University in Tokyo, Japan.
RICHARD DUNNING, 52, has served as a member of the Board of
Directors of the Company since his election in August 1997. He has been
President and Chief Executive Officer of VIMRX Pharmaceuticals Inc. since April
1996. VIMRX, a development stage biotechnology company based in Wilmington, DE,
is comprised of a diverse portfolio of companies, technologies and compounds.
Prior to joining VIMRX, Mr. Dunning spent most of his career with The DuPont
Company in a number of operating and financial positions. Mr. Dunning played an
instrumental role in the formation of The DuPont Merck Pharmaceutical Company
and acted as that organization's Executive Vice President and Chief Financial
Officer from 1991 to 1995. Mr. Dunning received a B.S. in Economics and an
M.B.A. in Finance from the University of Delaware.
STEVE H. KANZER, C.P.A., J.D., 34, has served as a member of the
Board of Directors of the Company since his election in June 1996. Mr. Kanzer is
a Senior Managing Director of Paramount Capital, Inc., a biotechnology
investment bank, and Paramount Capital Investments, LLC, a biotechnology venture
capital and merchant banking group. Mr. Kanzer is a founder and currently a
director of Boston Life Sciences, Inc., a biotech company, and Atlantic
Pharmaceuticals, Inc., a biotech company, and is currently Chairman of the Board
of Directors of Discovery Laboratories, Inc. He has been a founder and director
of several other public and private biotechnology companies, including Avigen,
Inc., Titan Pharmaceuticals, Inc. and
2
<PAGE> 6
Xenometrix, Inc. Prior to 1995, Mr. Kanzer was General Counsel of The Castle
Group Ltd. Before joining Paramount Capital, Inc. and The Castle Group Ltd., Mr.
Kanzer was an attorney at the law firm of Skadden, Arps, Meagher, Slate & Flom.
Mr. Kanzer received his J.D. from New York University School of Law and a B.B.A.
in Accounting from Baruch College.
PAUL D. RUBIN, M.D., 44, has served as a member of the Board of
Directors of the Company since his election in November 1997. Since 1996, he has
served as Senior Vice President for Drug Development at Sepracor, Inc. where he
is responsible for managing research and development programs for the company's
improved chemical entities portfolio, which includes the management of Discovery
Research, Regulatory, Clinical, Preclinical, and Project Management teams. Dr.
Rubin also plays a key role in the evaluation of external technology and
licensing opportunities. From 1993 to 1996, Dr. Rubin was the Vice President and
Worldwide Director of Early Clinical Development and Clinical Pharmacology at
Glaxo Wellcome. Prior to Glaxo, Dr. Rubin held various executive research
positions at Abbott Laboratories. Dr. Rubin received his M.D. from Rush Medical
College in Chicago and completed his residency in Internal Medicine at the
University of Wisconsin Hospitals and clinics in Madison, Wisconsin.
H. LAURENCE SHAW, M.D., 51, has served as a member of the Board of
Directors of the Company since his election in August 1997. He has been
Chairman, President and Chief Executive Officer of Pacific Pharmaceuticals, Inc.
("Pacific") since December 1996. Pacific is engaged in the development and
commercialization of medical products based on biotechnological research
regarding the treatment and detection of cancer and other diseases. From 1995 to
1996, Dr. Shaw was Corporate Vice President Research and Development for C.R.
Bard, Inc. in New Jersey. From September 1993 to 1995, he was Founder, President
and Chief Executive Officer of Atlantic Pharmaceuticals, Inc. Dr. Shaw graduated
from University College Hospital Medical School, London, England.
ANDREW STEIN, has served as a member of the Board of Directors of
the Company since January 1998. He is a founder and equity participant in
Metromedia Asia Limited, a telecommunication venture in China.
KENNETH TEMPERO, M.D., PH.D., M.B.A., 58, has served as a member of
the Board of Directors since September 1996. Prior thereto, he served as
Chairman and Chief Executive officer of MGI Pharma, Inc., a company that focuses
on the development and sale of cancer therapeutics and related products. From
November 1983 to August 1987, Dr. Tempero held various positions with G.D.
Searle & Co., a pharmaceutical company, most recently as Senior Vice President
of Research and Development. Dr. Tempero holds M.S. and Ph.D. degrees in
Pharmacology from Northwestern University, an M.D. in Medicine and Surgery from
Northwestern University and an M.B.A. in Pharmaceutical Marketing from Fairleigh
Dickinson University.
STEVEN THORNTON, 40, has served as a member of the Board of
Directors since February 1998. Has has served as Executive Vice President of
Commercial Development for Elan Pharmaceutical Technologies ("EPT") since
December 1997. Prior to joining EPT, Mr. Thornton served from July 1994 as
President of Schein Bayer Pharmaceutical Services Inc., a joint venture of Bayer
and Schein Pharmaceutical Inc. From 1991 to 1994, he served with Bayer as Region
Director with responsibility for pharmaceutical operations in Australia, New
Zealand and South Africa. Mr. Thornton graduated with honors from Lancaster
University in 1978, receiving a B.A. in applied social psychology.
COMMITTEES OF THE BOARD OF DIRECTORS
The Audit Committee of the Board of Directors reviews, acts on and
reports to the Board of Directors with respect to various auditing and
accounting matters, including the selection of the Company's independent public
accountants, the scope of the annual audits, fees to be paid to the auditors,
the performance of the Company's auditors and the accounting practices of the
Company. Mr. Dunning, chairman of the Committee, and Dr. Rubin are the only
members of the Audit Committee.
The Compensation Committee of the Board of Directors determines the
salaries and incentive compensation of the officers of the Company and provides
recommendations for the salaries and
3
<PAGE> 7
incentive compensation of the other employees and consultants of the Company.
The Compensation Committee also administers various incentive compensation,
stock and benefit plans. Dr. Tempero, chairman of the Committee, and Dr. Shaw
are the only members of the Compensation Committee.
The Executive Committee of the Board of Directors acts on such
matters as are referred to it by the full Board of Directors. Dr. Tempero and
Messrs. Kanzer and Rosen are the only members of the Executive Committee.
ATTENDANCE AT BOARD AND COMMITTEE MEETINGS
During the year ended December 31, 1997, the Board of Directors
held seven formal meetings. During this period, each incumbent Director attended
at least 75% of the aggregate number of meetings of the Board of Directors and
the total number of meetings held by all Committees on which he served. In
addition to formal meetings, the Board of Directors and the Audit and
Compensation Committees meet frequently on an informal basis.
COMPENSATION OF DIRECTORS
Cash Compensation. Directors do not receive a fee for attending
Board of Directors or committee meetings, but are reimbursed for expenses
incurred in connection with performing their respective duties as Directors of
the Company.
Stock Option Grant. Under the Automatic Option Grant Program of
the Amended and Restated 1995 Omnibus Incentive Plan (the "Option Plan"), each
individual serving as a non-employee Board member on October 21, 1997 was
granted, subject to stockholder approval of Proposal 3, an option to purchase
42,000 shares of Common Stock at an exercise price of $2.46875 per share, the
fair market value per share of Common Stock on the option grant date. Subject to
approval of Proposal 3, each individual who becomes a non-employee member after
October 21, 1997 will receive an option grant for 42,000 shares on the date such
individual first joins the Board. In addition, each non-employee Board member
who continues to serve on the Board will automatically be granted an option to
purchase an additional 12,000 shares of Common Stock on the date of the second
anniversary of such individual's initial 42,000-share option grant and on every
two (2) years thereafter. For further information regarding the terms of such
options, please see the description of the Automatic Option Grant Program in
Proposal 3 below.
EXECUTIVE OFFICERS
The names of the Company's executive officers as of March 16, 1998
and certain information about them are set forth below.
<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
Michael S. Rosen 45 President, Chief Executive Officer and
Director
Rickey Wilson, M.D., J.D. 49 Executive Vice President, Clinical Development
and Regulatory Affairs
Robert N. Brey, Ph.D. 48 Vice President, Research and Development
David G. Franckowiak, CPA 35 Vice President, Finance and Administration,
Treasurer and Corporate Secretary
</TABLE>
Information regarding executive officers who are not Directors is
as follows:
RICKEY WILSON, M.D., M.S., J.D., has been Executive Vice President
and Chief Scientific Officer of Endorex's majority-owned subsidiary, Wisconsin
Genetics, Inc., since November 1997 and Executive Vice President, Clinical
Development and Regulatory Affairs for the Company since January 1998. From
November 1995 until November 1997, Dr. Wilson had served as Vice President of
Corporate Regulatory Affairs, Pharmacia and Upjohn. He served as Vice President
of Worldwide Regulatory Affairs for Upjohn from January 1995 to November 1995
and as Vice President and Director, Human Pharmaceutical Regulatory Affairs and
Safety, Syntex from July 1990 to December 1994. Dr. Wilson graduated with honors
from the University of Texas at Austin. He received an M.D. from the University
of Texas Health Sciences
4
<PAGE> 8
Center at San Antonio. He also holds an M.S. in epidemiology from Columbia
University and a J.D. with honors from the University of San Francisco School of
Law. He completed his residency in pediatrics, and was a Fellow in pediatric
infectious diseases at St. Jude's Children Research Hospital in Memphis.
ROBERT N. BREY, PH.D. has served as Vice President, Research and
Development since January 1, 1998 and prior to then was Vice President, Vaccine
Development of the Company since December 1996. From 1994 to 1996, he served as
Principal of Vaccine Design Group, a consulting practice focused on research and
development strategies in vaccines and immunological therapies. From 1992 to
1994, Dr. Brey served as Director of Research at Vaxcel, Inc., a company
involved in vaccine delivery technology. From 1986 to 1992, he held a variety of
positions at Lederle-Praxis Biologicals, where he managed the Molecular Biology
and Oral Vaccine Development areas. Dr. Brey received a B.S. in Biology from
Trinity College and a Ph.D. in Microbiology from the University of Virginia
School of Medicine. He also served as a Postdoctoral Fellow in biology at the
Massachusetts Institute of Technology. Dr. Brey has written numerous
publications and filed several patents in the area of vaccines.
DAVID G. FRANCKOWIAK, C.P.A., C.M.A., M.ACC. became Vice President,
Finance and Administration in January 1998, having served as
Controller/Treasurer since April 1997. He was also appointed Corporate Secretary
in July 1997. From 1985 to March 1997, Mr. Franckowiak held several positions
with Coopers & Lybrand, the last of which was audit manager. Mr. Franckowiak
received his B.S. in Commerce, Accountancy and a Master of Accountancy at DePaul
University. He is also a Certified Public Accountant and a Certified Management
Accountant. He currently serves as the President of the board of directors of
the non-profit organization, Community Support Services, Inc., which position he
has held since July 1996, and from March 1994 to July 1996, he was the Treasurer
of such organization.
DIRECTOR AND OFFICER SECURITIES REPORTS
The Federal securities laws require the Company's Directors and
executive officers, and persons who own more than 10% of a registered class of
the Company's equity securities to file with the Securities and Exchange
Commission initial reports of ownership and reports of changes in ownership of
any equity securities of the Company. Copies of such reports are required to be
furnished to the Company. To the Company's knowledge, based solely on review of
the copies of such reports furnished to the Company, all of such persons subject
to these reporting requirements filed the required reports on a timely basis
with respect to the Company's most recent fiscal year, except that Richard
Dunning, H. Laurence Shaw and Paul Rubin each filed a late Form 3 and Michael
Rosen, Richard Dunning, Steve Kanzer, Paul Rubin, H. Laurence Shaw, Kenneth
Tempero and Robert Brey each filed a late Form 4.
5
<PAGE> 9
EXECUTIVE COMPENSATION
The following table sets forth information concerning the
compensation paid during the Company's fiscal years ended December 31, 1997 and
1996 and the fiscal year ended January 31, 1996 to (i) the Company's Chief
Executive Officer and (ii) all of the other executive officers whose base salary
during the year was in excess of $100,000 (collectively, the "Named Executive
Officers").
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
ANNUAL COMPENSATION
--------------------------------- SECURITIES UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY($) BONUS($) OPTIONS (#) COMPENSATION ($)
- --------------------------- -------- ---------- --------- --------------------- ----------------
<S> <C> <C> <C> <C> <C>
Michael S. Rosen 12/31/97 209,882 100,000(1) 650,000 4,600(6)
President & CEO 12/31/96 73,536 0(2) 46,667(5) 4,600(6)
1/31/96 -- -- -- --
Robert N. Brey 12/31/97 104,778 16,913(3) 50,000 0
Vice President 12/31/96 8,180 0(4) 6,667(5) 0
1/31/96 -- -- -- --
Gerald J. Vosika, M.D.(7) 12/31/97 225,000 0 25,000 0
Chairman and 12/31/96 234,471 0 133,334 0
Scientific Director 1/31/96 213,560 0 0 0
</TABLE>
(1) Includes 1997 bonus of $100,000 accrued in 1997 and paid in 1998.
(2) Mr. Rosen joined the Company on August 19, 1996.
(3) Includes 1997 bonus of $16,913 accrued in 1997 and paid in 1998.
(4) Dr. Brey joined the Company on December 1, 1996.
(5) Options granted in 1996 were cancelled as partial compensation for 1997
grants.
(6) Comprised of life insurance premium.
(7) Dr. Vosika resigned in February 1998.
OPTIONS AND STOCK APPRECIATION RIGHTS
The following table sets forth certain information concerning
options granted to the Named Executive Officers during the fiscal year ended
December 31, 1997. No SARs were granted during the period.
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
PERCENT
SECURITIES OF TOTAL
UNDERLYING OPTIONS EXERCISE EXPIRATION
OPTIONS GRANTED GRANTED(1) PRICE DATE
--------------- ---------- -------- ----------
<S> <C> <C> <C> <C>
Michael S. Rosen(2) 650,000 63.67% $2.46875 10/21/07
Robert N. Brey(2) 50,000 4.90% $2.46875 10/21/07
Gerald J. Vosika, M.D. 25,000 2.45% $2.46875 10/21/07
</TABLE>
(1) Based on an aggregate of 1,020,833 options granted to employees in the
fiscal year ended December 31, 1997, including options granted to the Named
Executive Officers.
(2) The options were granted on October 21, 1997 in cancellation of two options
previously granted with exercise price in excess of $2.46875 per share. The
option may be exercised to extent of 12.5% of the option shares on January
21, 1998 and in 14 equal installments quarterly thereafter, provided the
optionee is in service to the Company through each such exercise date. Each
option will become immediately exercisable for all of the option shares in
the event the Company is acquired by merger or sale of substantially all of
the Company's assets or outstanding Common Stock, unless the option is
assumed or otherwise replaced by the acquiring entity. The Compensation
Committee has authority to provide for the acceleration of each option in
connection with certain terminations following certain acquisitions, hostile
6
<PAGE> 10
tender offers or proxy contests for Board membership. Each option includes
a limited stock appreciation right pursuant to which the option may be
surrendered upon the occurrence of certain hostile tender offers, in return
for a cash distribution from the Company based on the tender offer price
per share. Each option has a maximum term of 10 years, subject to earlier
termination in the event of the optionee's cessation of service with the
Company.
The following table sets forth certain information concerning
exercisable and unexercisable stock options held as of December 31, 1997 by each
of the Named Executive Officers:
AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF UNEXERCISED VALUE OF UNEXERCISED
OPTIONS IN-THE-MONEY OPTIONS(1)
---------------------------- ----------------------------
EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Michael Rosen -- 650,000 -- $ 1,807,813
Robert Brey -- 50,000 -- $ 139,063
Gerald Vosika 25,000 $69,531 --
</TABLE>
(1) Based upon the difference between the bid price on December 31, 1997 ($5.25)
and exercise price.
EMPLOYMENT AGREEMENTS AND CHANGE IN CONTROL ARRANGEMENTS.
On June 1, 1996, the Company entered into an Employment Agreement
with Gerald Vosika, M.D., which agreement was amended by a letter agreement
dated June 25, 1996, to serve as the Chairman of the Board and Scientific
Director of the Company. Dr. Vosika's employment with the Company was to
terminate on May 31, 1999. Dr. Vosika's initial salary pursuant to the agreement
was $225,000. On February 11, 1998, Dr. Vosika resigned as Chairman, member of
the Board of Directors and Scientific Director. At that time, the Company
entered into a consulting agreement with Dr. Vosika, which provides for
consulting fees to be paid to Dr. Vosika totalling $80,000 over the period from
February 1, 1998 to May 31, 1999.
On July 25, 1996, the Company entered into an employment agreement
with Michael S. Rosen to serve as the President, Chief Executive Officer, and a
Director of the Company. The term of Mr. Rosen's employment agreement with the
Company commenced on August 19, 1996 and ends on August 30, 2000. Mr. Rosen's
initial salary pursuant to the agreement is $200,000. Mr. Rosen was elected a
Director of the Company on August 22, 1996.
On December 1, 1996, the Company entered into an employment
agreement with Robert N. Brey to serve as Vice President-Vaccine Development.
Dr. Brey's employment agreement with the Company commenced on December 1, 1996
and ends on November 30, 2000. Dr. Brey's initial salary pursuant to the
agreement is $100,000.
The Compensation Committee has the authority to provide for the
accelerated vesting of the options granted to the Chief Executive Officer and
the Company's other executive officers under the Option Plan (including any
options granted under the Company's predecessor 1994 Non-Employee Stock Option
Plan and Incentive Stock Option Plan) in the event of (i) a change in control of
the Company effected through a successful tender offer for more than 50% of the
Company's outstanding Common Stock or a change in the majority of the Board as a
result of one or more contested elections for Board membership, or (ii) the
individual's termination of employment (whether involuntarily or through a
forced resignation) within a designated period following such a change in
control or an acquisition of the Company by merger or asset sale.
LIMITATION OF LIABILITY AND INDEMNIFICATION MATTERS
The Company's Certificate of Incorporation provides that, except to
the extent prohibited by the Delaware General Corporation Law, its directors
shall not be personally liable to the Company or its
7
<PAGE> 11
stockholders for monetary damages for any breach of fiduciary duty as directors
of the Company. Under Delaware law, the directors have a fiduciary duty to the
Company which is not eliminated by this provision of the Certificate of
Incorporation and, in appropriate circumstances, equitable remedies such as
injunctive or other forms of non-monetary relief will remain available. In
addition, each director will continue to be subject to liability under Delaware
law for breach of the director's duty of loyalty to the Company for acts or
omissions which are found by a court of competent jurisdiction to be not in good
faith or involving intentional misconduct, for knowing violations of law, for
actions leading to improper personal benefit to the director, and for payment of
dividends or approval of stock repurchases or redemptions that are prohibited by
Delaware law. This provision also does not affect the directors'
responsibilities under any other laws, such as the Federal securities laws or
state or Federal environmental laws. In addition, the Company has obtained
liability insurance for its officers and directors.
The Certificate of Incorporation also provides that the Company
shall indemnify, to the fullest extent permitted by Section 145 of the Delaware
General Corporation Law, all of its present and former officers and directors,
and any party agreeing to serve as an officer, director or trustee of any entity
at the Company's request, in connection with any civil or criminal proceeding
threatened or instituted against such party by reason of actions or omissions
while serving in such capacity. Indemnification by the Company includes payment
of expenses in defense of the indemnified party in advance of any proceeding or
final disposition thereof. The rights to indemnification provided in this
provision do not preclude the exercise of any other indemnification rights by
any party pursuant to any law, agreement or vote of the stockholders or the
disinterested directors of the Company.
Section 145 of the Delaware General Corporation Law generally
allows the Company to indemnify the parties described in the preceding paragraph
for all expenses, judgments, fines and amounts in settlement actually paid and
reasonably incurred in connection with any proceedings so long as such party
acted in good faith and in a manner reasonably believed to be in or not opposed
to the Company's best interests and, with respect to any criminal proceedings,
if such party had no reasonable cause to believe his or her conduct to be
unlawful. Indemnification may only be made by the Company if the applicable
standard of conduct set forth in Section 145 has been met by the indemnified
party upon a determination made (1) by the Board of Directors by a majority vote
of a quorum of directors who are not parties to such proceedings, or (2) if such
a quorum is not obtainable or if directed by a quorum of disinterested
directors, by independent legal counsel in a written opinion, or (3) by the
stockholders.
8
<PAGE> 12
REPORT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
The Compensation Committee of the Board of Directors advises the
Chief Executive Officer and the Board of Directors on matters of the Company's
compensation philosophy and the compensation of executive officers and other
individuals compensated by the Company. The Compensation Committee also is
responsible for the administration of the Company's Option Plan under which
option grants may be made to executive officers. The Compensation Committee has
reviewed and is in accord with the compensation paid to executive officers in
fiscal year 1997.
GENERAL COMPENSATION POLICY. The fundamental policy of the
Compensation Committee is to provide the Company's executive officers with
competitive compensation opportunities based upon their contribution to the
development and financial success of the Company and their personal performance.
It is the Compensation Committee's objective to have a portion of each executive
officer's compensation contingent upon the Company's performance as well as upon
such executive officer's own level of performance. Accordingly, the compensation
package for each executive officer is comprised of two elements: (i) base salary
and annual bonus which reflect individual performance and is designed primarily
to be competitive with cash compensation levels in the industry and (ii)
long-term stock-based incentive awards which strengthen the mutuality of
interests between the executive officers and the Company's stockholders.
FACTORS. The principal factors which the Compensation Committee
considered with respect to each executive officer's compensation package for
fiscal year 1997 are summarized below. The Compensation Committee may, however,
in its discretion apply entirely different factors in advising the Chief
Executive Officer and the Board of Directors with respect to executive
compensation for future years.
BASE SALARY. The suggested base salary for each executive officer
is determined on the basis of the following factors: experience, personal
performance, the salary levels in effect for comparable positions within and
without the industry and internal base salary comparability considerations. The
weight given to each of these factors differs from individual to individual, as
the Compensation Committee deems appropriate.
From time to time, the Compensation Committee may advocate cash
bonuses when such bonuses are deemed to be in the best interest of the Company.
LONG-TERM INCENTIVE COMPENSATION. Long-term incentives are
provided through grants of stock options. The grants are intended to align the
interests of each executive officer with those of the stockholders and to
provide each individual with a significant incentive to manage the Company from
the perspective of an owner with an equity stake in the Company. Each option
grant allows the individual to acquire shares of the Company's Common Stock at a
fixed price per share (generally, the market price on the grant date) over a
specified period of time (up to ten years). Each option generally becomes
exercisable in installments over a four-year period, contingent upon the
executive officer's continued employment with the Company. Accordingly, the
option grant will provide a return to the executive officer only if the
executive officer remains employed by the Company during the vesting period, and
then only if the market price of the underlying shares appreciates.
The number of shares subject to each option grant is set at a level
intended to create a meaningful opportunity for stock ownership based on the
executive officer's current position with the Company, the base salary
associated with that position, the size of comparable awards made to individuals
in similar positions within the industry, the individual's potential for
increased responsibility and promotion over the option term and the individual's
personal performance in recent periods. The Compensation Committee also
considers the number of unvested options held by the executive officer in order
to maintain an appropriate level of equity incentive for that individual.
However, the Compensation Committee does not adhere to any specific guidelines
as to the relative option holdings of the Company's executive officers.
CEO COMPENSATION. In advising the Board of Directors with respect
to the compensation payable to the Company's Chief Executive Officer, the
Compensation Committee seeks to achieve two objectives: (i) establish a level of
base salary competitive with that paid by companies within the industry which
are of comparable size to the Company and by companies outside of the industry
with which the
9
<PAGE> 13
Company competes for executive talent and (ii) to make a significant percentage
of the total compensation package contingent upon the Company's performance and
stock price appreciation.
The suggested base salary established for Mr. Rosen on the basis of
the foregoing criteria was intended to provide a level of stability and
certainty each year. Accordingly, this element of compensation was not affected
to any significant degree by Company performance factors. At the end of the
first year of employment, Mr. Rosen was entitled to a bonus of up to $100,000
based on mutually agreed milestones. In addition, at the discretion of the Board
of Directors, Mr. Rosen was also eligible for an additional bonus of up to
$100,000. In February 1998, the Board of Directors paid Mr. Rosen a bonus of
$100,000 for meeting the 1997 Company objectives. Upon his employment by the
Company, Mr. Rosen was granted options to purchase 46,667 shares of Common Stock
(as adjusted for the reverse stock split effected in June 1997). Such options
vested 6,667 on August 19, 1996 and 1,667 on September 30, 1996 and each quarter
thereafter. On October 21, 1997, the Board of Directors offered to cancel that
option and regrant an option for 46,667 shares in replacement thereof and made
an additional grant of 603,333 shares of Common Stock. Such options shall become
exercisable with respect to 81,250 shares on January 21, 1998 and 40,625 shares
in fourteen (14) successive equal quarterly installments upon completion of each
additional three (3) months of service over the next forty-two (42) month period
thereafter.
OPTION REPRICING. During the 1997 fiscal year, the Compensation
Committee felt that circumstances had made it necessary for the Company to
implement an option cancellation/regrant program. Accordingly, on October 21,
1997, all of the Company's employees (including executive officers) and non-
employee Board members were given the opportunity to surrender their outstanding
options under the Option Plan with exercise prices in excess of $2.46875 per
share in return for a new option grant for the same number of shares but with a
lower exercise price of $2.46875 per share, the fair market value per share of
the Company's Common Stock on the regrant date. Each employee eligible for a new
option grant was given the choice of accepting that option with a new vesting
schedule in cancellation of his or her higher-priced option or rejecting the new
grant and retaining the higher-priced option with its original vesting schedule.
The Compensation Committee determined that this program was
necessary because equity incentives are a significant component of the total
compensation package of each Company employee and play a substantial role in the
Company's ability to retain the services of individuals essential to the
Company's long-term financial success. The Compensation Committee felt that the
Company's ability to retain key employees and non-employee Board members would
be significantly impaired, unless value were restored to their options in the
form of regranted options at the current market price of the Company's Common
Stock. However, in order for the regranted options to serve their primary
purpose of assuring the continued service of each optionee, a new vesting
schedule was imposed with respect to the option shares. The new options will
become exercisable with respect to 12.5% of the option shares upon the
optionee's completion of three (3) months of service measured from the regrant
date and with respect to the balance of the shares in a series of 14 successive
equal quarterly installments upon the optionee's completion of each additional
three (3) months of service over the 42-month period thereafter. Accordingly,
each optionee will only have the opportunity to acquire the option shares at the
lower exercise price if he or she remains in the Company's employ.
As a result of the new exercise schedules imposed on the regranted
options, the Compensation Committee believes that the program strikes an
appropriate balance between the interests of the option holders and those of the
stockholders. The lower exercise prices in effect under the regranted options
make those options valuable once again to the executive officers and key
employees critical to the Company's financial performance. However, those
individuals will enjoy the benefits of the regranted options only if they in
fact remain in the Company's employ and contribute to the Company's financial
success.
COMPLIANCE WITH INTERNAL REVENUE CODE SECTION 162(M). As a result
of Section 162(m) of the Internal Revenue Code of 1986, as amended, which was
enacted into law in 1993, the Company will not be allowed a federal income tax
deduction for compensation paid to certain executive officers, to the extent
that compensation exceeds $1 million per officer in any one year. This
limitation will apply to all compensation paid to the covered executive officers
which is not considered to be performance based. Compensation which does qualify
as performance-based compensation will not have to be taken into
10
<PAGE> 14
account for purposes of this limitation. The Omnibus Plan (as amended subject to
stockholder approval) contains certain provisions which are intended to assure
that any compensation deemed paid in connection with the exercise of stock
options granted under that plan with an exercise price equal to the market price
of the option shares on the grant date will qualify as performance-based
compensation.
The Compensation Committee does not expect that the compensation to
be paid to the Company's executive officers for the 1998 fiscal year will exceed
the $1 million limit per officer. Because it is very unlikely that the cash
compensation payable to any of the Company's executive officers in the
foreseeable future will approach the $1 million limit, the Compensation
Committee has decided at this time not to take any other action to limit or
restructure the elements of cash compensation payable to the Company's executive
officers. The Compensation Committee will reconsider this decision should the
individual compensation of any executive officer ever approach the $1 million
level.
THE COMPENSATION COMMITTEE
Dr. Kenneth Tempero
Dr. H. Laurence Shaw
March 18, 1998
11
<PAGE> 15
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of March 16, 1998, certain
information with respect to the beneficial ownership of shares of Common Stock
of: (i) each person who is known to the Company to be the beneficial owner of
more than five percent of the Company's Common Stock, (ii) each Director of the
Company and each Named Executive Officer, and (iii) all directors and executive
officers of the Company as a group. As of March 16, 1998, the Company had
9,936,000 shares of Common Stock outstanding.
<TABLE>
<CAPTION>
NO. OF SHARES
NAME AND ADDRESS OF BENEFICIAL OWNER BENEFICIALLY OWNED(1) PERCENT OF CLASS
------------------------------------ --------------------- ----------------
<S> <C> <C>
The Aries Trust(2)(3)
c/o Paramount Capital Asset Management, Inc.
787 Seventh Avenue,
New York, NY 10019 1,742,980 17.27%
Aries Domestic Fund(2)(4)
c/o Paramount Capital Asset Management, Inc.
787 Seventh Avenue,
New York, NY 10019 802,431 8.01%
Elan International Services, Ltd.
102 St. James Court
Flatts Smith, SL 04
Bermuda 1,606,462 14.30%
Lindsay A. Rosenwald, M.D.(6)
787 Seventh Avenue,
New York, NY 10019 1,434,032 12.61%
Michael S. Rosen, MBA(7)(8) 121,875 1.21%
Steve H. Kanzer, Esq.(2)(9)
c/o Paramount Capital Investments, LLC
787 Seventh Avenue,
New York, NY 10019 146,500 1.45%
Richard Dunning(7) 1,500 **
Paul Rubin(7) 0 **
H. Laurence Shaw(7) 1,500 **
Andrew Stein(7) 1,500 **
Kenneth Tempero(7)(10) 26,500 **
Steven Thornton(7) 0 **
Rickey Wilson(7) 0 **
Robert N. Brey(7)(11) 9,375 **
David G. Franckowiak(7)(11) 9,375 **
All Directors and Officers as a group 318,125 3.10%
</TABLE>
** Represents less than 1% of outstanding Common Stock or voting power.
(1) Shares of the Company's Common Stock which any person or entity set forth
in this table has a right to acquire, pursuant to the exercise of options
or warrants, are deemed to be outstanding for the purpose of computing the
percentage ownership of such person or entity, but are not deemed
outstanding for the purpose of computing the percentage ownership of any
other person or entity.
(2) Lindsay A. Rosenwald, M.D., is the President and sole stockholder of
Paramount Capital Asset Management, Inc., the Investment Manager and
General Partner of the Aries Trust and Aries Domestic Fund, L.P.,
respectively. Dr. Rosenwald disclaims beneficial ownership of the shares
owned by Aries Funds except to the extent of his pecuniary interest
therein, if any.
(3) Includes 155,493 shares issuable upon exercise of warrants that are
exercisable within the 60-day period following March 16, 1998.
12
<PAGE> 16
(4) Includes 79,866 shares issuable upon exercise of warrants that are
exercisable within the 60-day period following March 16, 1998.
(5) Includes 1,068,000 shares issuable upon conversion of Series B Preferred
Stock and 230,770 shares issuable upon exercise of warrants that are
exercisable within the 60-day period following March 16, 1998.
(6) Includes 1,434,033 shares issuable upon exercise of warrants that are
exercisable within the 60-day period following March 16, 1998.
(7) The address of this individual is c/o Endorex Corp., 900 North Shore Drive,
Lake Bluff, IL 60044.
(8) Consists of 121,875 shares issuable upon exercise of options held that are
exercisable within the 60-day period following March 16, 1998.
(9) Consists of 146,500 shares issuable upon exercise of options held that are
exercisable within the 60-day period following March 16, 1998.
(10) Consists of 26,500 shares issuable upon exercise of options held that are
exercisable within the 60-day period following March 16, 1998.
(11) Consists of 9,375 shares issuable upon exercise of options held that are
exercisable within the 60-day period following March 16, 1998.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
On June 13, 1996, Dominion Resources, Inc. ("Dominion") entered
into an agreement with The Aries Fund and the Aries Domestic Fund, L.P.
(collectively, the "Aries Funds"), with the Company as a party to the agreement,
whereby Dominion sold and the Aries Funds purchased an aggregate of 266,667
shares of Common Stock at price of $1.50 per share. The purchase price was paid
from the Aries Funds' general funds. As part of the transaction, Dominion
transferred to the Aries Funds certain of its rights under an existing agreement
with the Company including, among others, the right to designate a director of
the Company and the right to have the shares registered under the Securities Act
of 1933, as amended (the "Securities Act"). Upon completion of the sale of the
266,667 shares, Steve Kanzer was elected to the Board as the designee of the
Aries Funds. On June 26, 1996, the Aries Funds purchased from the Company an
additional 333,334 shares of Common Stock at a price of $3.00 per share. The
purchase price was paid from the Aries Funds' general funds. The purchase
agreement relating to such shares contains various representations and
warranties concerning the Company and its activities and also various
affirmative and negative covenants. The purchase agreement grants to the Aries
Funds the right to have the shares registered under the Securities Act. The
agreement restricts the Company from entering into mergers, acquisitions, or
sales of its assets without the prior approval of the Aries Funds.
In connection with a senior line of credit agreement entered into
by the Company with the Aries Funds, on May 19, 1997, the Company granted
warrants to purchase an aggregate of 66,668 shares of Common Stock at an initial
exercise price equal to the offering price of the Company's Private Placement
(as defined below), subject to adjustment under certain circumstances. Such
warrants are exercisable from May 19, 1997 until May 19, 2002. Paramount Capital
Asset Management, Inc. ("PCAM") is the investment manager of The Aries Fund and
the general partner of the Aries Domestic Fund, L.P. Lindsay Rosenwald, M.D., is
the president sole stockholder of PCAM and of the Placement Agent (as defined
below).
Pursuant to a private placement (the "Private Placement") of Common
Stock, the Company issued and sold an aggregate of 8,648,716 shares of Common
Stock to certain accredited investors on July 16, October 10 and October 16,
1997, in consideration of an aggregate amount of $20,000,000. The net proceeds
to the Company after deducting commissions and expenses of Paramount Capital,
Inc., which acted as the placement agent for the Private Placement (the
"Placement Agent"), were $17,400,000.
In connection with the Private Placement, the Company issued and
sold to the Placement Agent and/or its designees warrants (the "Placement
Warrants") to purchase up to an aggregate of 864,865 shares of Common Stock and,
in connection with the execution of a financial advisory agreement, dated
October 16, 1997, between the Company and the Placement, the Company issued and
sold to the Placement
13
<PAGE> 17
Agent warrants (the "Advisory Warrants") to purchase up to an aggregate of
1,297,297 shares of Common Stock. The Placement Warrants and the Advisory
Warrants are exercisable beginning on April 16, 1998 until April 16, 2003, at an
exercise price of $2.54375 per share, subject to adjustment under certain
circumstances.
On January 21, 1998, the Company established a joint venture with
Elan Corporation plc ("Elan") for the exclusive research, development and
commercialization of oral and mucosal prophylactic and therapeutic vaccines. As
part of the transaction, Elan International Services, Ltd. ("EIS"), a wholly
owned subsidiary of Elan, made a $2,000,000 initial investment in the Company
through purchasing 307,692 shares of Common Stock and warrants to acquire
230,770 shares of Common Stock at an exercise price of $10.00 per share with a
term of 6 years. In addition, in connection with the joint venture and the
execution of a license agreement, the Company issued $8.01 million of
convertible preferred stock to EIS.
See "Proposal 1, Election of Directors -- Compensation of
Directors,"-- Executive Compensation" and "-- Employment Agreements" for
information concerning employment agreements with and options to purchase Common
Stock granted to officers and directors of the Company.
PROPOSAL 2
SELECTION OF AN INDEPENDENT PUBLIC ACCOUNTANT AND AUDITOR
Upon the recommendation of the Audit Committee, the Board of
Directors appointed Coopers & Lybrand L.L.P., independent public accountants and
auditors of the Company, as auditors of the Company to serve for the year ending
December 31, 1998, subject to the ratification of such appointment by the
stockholders at the Annual Meeting. The affirmative vote of a plurality of the
Company's outstanding Common Stock present in person or by proxy is required to
ratify the appointment of the auditors. Unless otherwise instructed, the proxy
holders will vote the proxies received by them "FOR" the ratification of Coopers
& Lybrand L.L.P. to serve as the Company's auditors for the year ending December
31, 1998.
14
<PAGE> 18
PROPOSAL 3
APPROVAL OF THE AMENDED AND RESTATED 1995 OMNIBUS INCENTIVE PLAN
The Company's stockholders are being asked to approve the Amended
and Restated 1995 Omnibus Incentive Plan (the "Omnibus Plan"). The Omnibus Plan
was initially adopted by the Board on April 24, 1995. The plan was amended on
October 21, 1997 to increase the number of shares of Common Stock available for
issuance by 1,413,333 shares (after adjusting for the Reverse Stock Split
effected on June 11, 1997), subject to stockholder approval at the 1998 Annual
Meeting and to effect the other changes described below. The Omnibus Plan was
subsequently restated on February 11, 1998, subject to stockholder approval at
the 1998 Annual Meeting to increase the share reserve by an additional 500,000
shares.
The Omnibus Plan, as amended and restated, will effect the
following changes: (i) increase the number of shares of Common Stock available
for issuance by 1,913,333 shares, (ii) implement the salary investment option
grant, the automatic option grant and director fee option grant programs, (iii)
extend eligibility under the discretionary option grant program to non-employee
members of the Board and consultants and other advisors, (iv) allow any unvested
shares issued under the Omnibus Plan and subsequently repurchased by the Company
at the option exercise price paid per share to be reissued under the Omnibus
Plan, (v) eliminate the stock issuance and dividend equivalent right features of
the plan, (vi) incorporate the Company's existing 1994 Non-Employee Stock Option
Plan and the Incentive Stock Option Plan (collectively, the "Predecessor Plans")
so that the Omnibus Plan will serve as the successor to those plans and (vii)
effect a series of additional changes to the provisions of the Omnibus Plan
(including the stockholder approval requirements) in order to allow the Plan
Administrator more flexibility and to take advantage of the recent amendments to
Rule 16b-3 of the Securities Exchange Act of 1934, as amended. The Omnibus Plan,
as amended and restated, became effective on October 21, 1997, subject to
stockholder approval at the 1998 Annual Meeting, and all outstanding options
under the Predecessor Plans will be incorporated into the Omnibus Plan at the
time of such approval. The Predecessor Plans will terminate, and no further
option grants or share issuances will be made under the Predecessor Plans
thereafter. However, all outstanding options under the Predecessor Plans will
continue to be governed by the terms and conditions of the existing option
agreements for those grants.
The Omnibus Plan is designed to serve as a comprehensive equity
incentive program to attract and retain the services of individuals essential to
the Company's long-term growth and financial success. Accordingly, officers and
other key employees, non-employee Board members and consultants and other
advisors in the service of the Company or any subsidiary corporation will have
the opportunity to acquire a meaningful equity interest in the Company through
their participation in the Omnibus Plan.
SUMMARY
The following is a summary of the principal features of the Omnibus
Plan as amended and restated. The summary, however, does not purport to be a
complete description of all the provisions of the Omnibus Plan. Any stockholder
of the Company who wishes to obtain a copy of the actual plan document may do so
upon written request to the Corporate Secretary at the Company's principal
executive offices in Lake Bluff, Illinois.
EQUITY INCENTIVE PROGRAMS
The Omnibus Plan contains four separate equity incentive programs:
(i) a Discretionary Option Grant Program, (ii) a Salary Investment Option Grant
Program, (iii) an Automatic Option Grant Program and (iv) a Director Fee Option
Grant Program. The principal features of these programs are described below. The
Omnibus Plan (other than the Automatic Option Grant and Director Fee Option
Grant Programs) will be administered by the Compensation Committee of the Board.
This committee (the "Plan Administrator") will have complete discretion (subject
to the provisions of the Omnibus Plan) to authorize option grants under the
Omnibus Plan. However, all grants under the Automatic Option Grant and Director
Fee Option Grant Programs will be made in strict compliance with the provisions
of that program, and no
15
<PAGE> 19
administrative discretion will be exercised by the Plan Administrator with
respect to the grants made thereunder.
SHARE RESERVE
A total of 2,000,000 shares of Common Stock will be available for
issuance over the remaining term of the Omnibus Plan. This reserve is comprised
of the number of shares of Common Stock available for issuance under the
Predecessor Plans and the Omnibus Plan as of the date of adoption of the
restatement of the Omnibus Plan by the Board (including the 1,413,333-share
increase authorized by the Board) and the additional 500,000 share increase
authorized by the Board. However, this share reserve will automatically be
increased on the first trading day of each calendar year, beginning with the
1999 calendar year, by a number of shares equal to one percent (1%) of the total
number of shares of Common Stock outstanding on the last trading day in the
immediately preceding calendar year. In no event may any one participant in the
Omnibus Plan be granted stock options and separately exercisable stock
appreciation rights for more than 750,000 shares in any calendar year beginning
with the 1998 calendar year. Stockholder approvals of this Proposal will
constitute approval of such limit.
As of March 16, 1998, options for 1,516,839 shares of Common Stock
had been issued and not cancelled under the Omnibus Plan, the Predecessor Plans
and option not issued pursuant to a plan of which 33,667 shares were exercised
and 1,483,172 shares were outstanding. 483,161 shares of Common Stock remained
available for future option grants.
In the event any change is made to the outstanding shares of Common
Stock by reason of any recapitalization, stock dividend, stock split,
combination of shares, exchange of shares or other change in corporate structure
effected without the Company's receipt of consideration, appropriate adjustments
will be made to the securities issuable (in the aggregate and to each
participant) under the Omnibus Plan and to the securities and exercise price
under each outstanding option.
ELIGIBILITY
Officers and employees, non-employee Board members and consultants
and independent advisors in the service of the Company or any parent or
subsidiary corporation (whether now existing or subsequently established) will
be eligible to participate in the Discretionary Option Grant Program, and
officers and other highly compensated employees will also be eligible to
participate in the Salary Investment Option Grant Program. Only non-employee
members of the Board will be eligible to participate in the Automatic Option
Grant and Director Fee Option Grant Programs.
As of March 16, 1998, approximately 4 executive officers, 9 other
employees and 7 non-employee Board members were eligible to participate in the
Omnibus Plan, and 7 non-employee Board members were eligible to participate in
the Director Fee Option Grant Program.
VALUATION
The fair market value per share of Common Stock on any relevant
date under the Omnibus Plan will be the mean of the high bid and the low ask per
share on that date on the OTC Bulletin Board, or other market on which the
Common Stock trades. On March 16, 1998, the fair market price per share was
$6.25.
DISCRETIONARY OPTION GRANT PROGRAM
Options may be granted under the Discretionary Option Grant Program
at an exercise price per share not less than eighty five percent (85%) of the
fair market value per share of Common Stock on the option grant date. No granted
option will have a term in excess of ten years.
Upon cessation of service, the optionee will have a limited period
of time in which to exercise any outstanding option to the extent such option is
exercisable for vested shares. The Plan Administrator will have complete
discretion to extend the period following the optionee's cessation of service
during which his or
16
<PAGE> 20
her outstanding options may be exercised and/or to accelerate the exercisability
or vesting of such options in whole or in part. Such discretion may be exercised
at any time while the options remain outstanding, whether before or after the
optionee's actual cessation of service.
The Plan Administrator is authorized to issue two types of stock
appreciation rights in connection with option grants made under the
Discretionary Option Grant Program:
TANDEM STOCK APPRECIATION RIGHTS provide the holders with the
right to surrender their options for an appreciation distribution from
the Company equal in amount to the excess of (a) the fair market value
of the vested shares of Common Stock subject to the surrendered option
over (b) the aggregate exercise price payable for such shares. Such
appreciation distribution may, at the discretion of the Plan
Administrator, be made in cash or in shares of Common Stock.
LIMITED STOCK APPRECIATION RIGHTS may be granted to officers of
the Company as part of their option grants. Any option with such a
limited stock appreciation right in effect may be surrendered to the
Company upon the successful completion of a hostile take-over of the
Company. In return for the surrendered option, the officer will be
entitled to a cash distribution from the Company in an amount per
surrendered option share equal to the excess of (a) the take-over price
per share over (b) the exercise price payable for such share.
The Plan Administrator will have the authority to effect the
cancellation of outstanding options under the Discretionary Option Grant Program
which have exercise prices in excess of the then current market price of Common
Stock and to issue replacement options with an exercise price based on the
market price of Common Stock at the time of the new grant.
SALARY INVESTMENT OPTION GRANT PROGRAM
The Plan Administrator will have complete discretion in
implementing the Salary Investment Option Grant Program for one or more calendar
years and in selecting the executive officers and other eligible individuals who
are to participate in the program for those years. As a condition to such
participation, each selected individual must, prior to the start of the calendar
year of participation, file with the Plan Administrator an irrevocable
authorization directing the Company to reduce his or her base salary for the
upcoming calendar year by a designated multiple of one percent (1%). However,
the salary reduction amount may not be less than Ten Thousand Dollars ($10,000)
and may not be more than Seventy-Five Thousand Dollars ($75,000). To the extent
the Plan Administrator approves the salary reduction authorization, the
individual who filed that authorization will be granted an option under the
Salary Investment Option Grant Program on or before the last trading day in
January of the calendar year for which that salary reduction is to be in effect.
Stockholder approval of this Proposal will constitute pre-approval of each
option subsequently granted pursuant to the provisions of the Salary Investment
Option Grant Program and the subsequent exercise of that option in accordance
with its terms.
Each option will be subject to substantially the same terms and
conditions applicable to option grants made under the Discretionary Option Grant
Program, except for the following differences:
- The exercise price per share will be equal to one-third of the
fair market value per share of Common Stock on the option grant date,
and the number of option shares will be determined by dividing the total
dollar amount of the authorized reduction in the participant's base
salary by two-thirds of the fair market value per share of Common Stock
on the option grant date. As a result, the total spread on the option
(the fair market value of the option shares on the grant date less the
aggregate exercise price payable for those shares) will equal the dollar
amount of the optionee's base salary invested in the option.
- The option will become exercisable for the option shares in a
series of twelve successive equal monthly installments upon the
optionee's completion of each calendar month of service in the calendar
year for which the salary reduction is in effect.
17
<PAGE> 21
- Each option will remain outstanding for vested shares until
the earlier of (i) the expiration of the ten (10)-year option term or
(ii) the expiration of the three (3)-year period measured from the date
the optionee's service terminates.
AUTOMATIC OPTION GRANT PROGRAM
Under the Automatic Option Grant Program, each individual who was
serving as a non-employee Board member was automatically granted at that time an
option grant for 42,000 shares of Common Stock, subject to shareholder approval
of this Proposal 3. Each individual who first becomes a non-employee Board
member after such date, will automatically be granted at that time an option
grant for 42,000 shares of Common Stock. In addition, each individual who
continues to serve as a non-employee Board member will automatically be granted
an option to purchase 12,000 shares of Common Stock, on the second anniversary
of the initial 42,000-share option grant to such individual and every two (2)
years thereafter. There will be no limit on the number of such 12,000 share
options which any one non-employee Board member may receive over the period of
Board service. Stockholder approval of this Proposal will constitute
pre-approval of each option granted on or after the date of the Annual Meeting
pursuant to the provisions of the Automatic Option Grant Program and the
subsequent exercise of that option in accordance with its terms.
Each option will have an exercise price per share equal to 100% of
the fair market value per share of Common Stock on the option grant date and a
maximum term of ten years measured from the option grant date.
Each option will be immediately exercisable for all the option
shares, but any purchased shares will be subject to repurchase by the Company,
at the exercise price paid per share, upon the optionee's cessation of Board
service. Each initial 42,000-share option grant will vest (and the Company's
repurchase rights will lapse) (i) with respect to 30,000 shares in a series of
two (2) successive equal annual installments upon the optionee's completion of
each year of Board service over the two (2)-year period measured from the option
grant date and (ii) with respect to the balance of the shares in a series of
eight (8) successive equal quarterly installments on the last day of each
calendar quarter over the two (2)-year period measured from the option grant
date provided the optionee has attended the regular Board meeting held during
such quarter. Each 12,000-share option grant will vest (and the Company's
repurchase right will lapse) in a series of eight (8) successive equal quarterly
installments on the last day of each calendar quarter over the two (2)-year
period measured from the option grant date provided the optionee has attended
the regular Board meeting held during such quarter.
The shares subject to each automatic option grant will immediately
vest upon the optionee's death or permanent disability or an acquisition of the
Company by merger or asset sale or a hostile change in control of the Company
(whether by successful tender offer for more than 50% of the outstanding voting
stock or by proxy contest for the election of Board members). In addition, upon
the successful completion of a hostile take-over, each automatic option grant
may be surrendered to the Company for a cash distribution per surrendered option
share in an amount equal to the excess of (a) the take-over price per share over
(b) the exercise price payable for such share.
DIRECTOR FEE OPTION GRANT PROGRAM
Each non-employee Board member will have the right to apply all or
a portion of his total retainer fee otherwise payable in cash each year
(currently no retainer is paid) to the acquisition of a special option grant
under the Director Fee Option Grant Program. The grant will automatically be
made on the first trading day in January following the filing of the
stock-in-lieu-of-cash election and will have an exercise price per share equal
to one-third of the fair market value of the option shares on the grant date.
The number of shares subject to the option will be determined by dividing the
amount of the retainer fee applied to the program by two-thirds of the fair
market value per share of Common Stock on the grant date. As a result, the total
spread on the option (the fair market value of the option shares on the grant
date less the aggregate exercise price payable for those shares) will be equal
to the portion of the retainer fee invested in that option. Stockholder approval
of this Proposal will constitute pre-approval of each option subsequently
granted
18
<PAGE> 22
pursuant to the provisions of the Director Fee Option Grant Program and the
subsequent exercise of that option in accordance with its terms.
The option will become exercisable for fifty percent (50%) of the
option shares upon the optionee's completion of six (6) months of Board service
in the calendar year in which the option is granted, and the balance of the
option shares will become exercisable in a series of six (6) successive equal
monthly installments upon the optionee's completion of each additional month of
Board service during that calendar year. The option will remain exercisable for
such shares until the earlier of (i) the expiration of the ten (10)-year option
term or (ii) the end of the three (3)-year period measured from the date of the
optionee's cessation of Board service. The option will become immediately
exercisable for all the option shares should the optionee die or become
permanently disabled while a Board member. In addition, upon the successful
completion of a hostile take-over, each automatic option grant may be
surrendered to the Company for a cash distribution per surrendered option share
in an amount equal to the excess of (a) the take-over price per share over (b)
the exercise price payable for such share.
GENERAL PROVISIONS
ACCELERATION
In the event that the Company is acquired by merger or asset sale,
each outstanding option under the Discretionary Option Grant Program which is
not to be assumed by the successor corporation or replaced with a comparable
option to purchase shares of the capital stock of the successor corporation will
automatically accelerate in full. The Plan Administrator will have complete
discretion to grant one or more options under the Discretionary Option Grant
Program which will become fully exercisable for all option shares in the event
those options are assumed in the acquisition and the optionee's service is
involuntarily terminated within a designated period (not to exceed 18 months)
following such acquisition. The Plan Administrator will have similar discretion
to grant options which will become fully exercisable for all the option shares
upon a hostile change in control of the Company (whether by successful tender
offer for more than 50% of the outstanding voting stock or by proxy contest for
the election of Board members) or upon the subsequent termination of the
individual's service within a designated period (not to exceed 18 months). Each
option outstanding under the Salary Investment Option Grant and Director Fee
Option Grant Programs will automatically accelerate in the event of such an
acquisition or hostile change in control of the Company.
The acceleration of vesting in the event of a change in the
ownership or control of the Company may be seen as an anti-takeover provision
and may have the effect of discouraging a merger proposal, a takeover attempt or
other efforts to gain control of the Company.
FINANCIAL ASSISTANCE
The Plan Administrator may permit one or more participants to pay
the exercise price of outstanding options or the purchase price of shares under
the Omnibus Plan by delivering a promissory note payable in installments. The
Plan Administrator will determine the terms of any such promissory note.
However, the maximum amount of financing provided any participant may not exceed
the cash consideration payable for the issued shares plus all applicable taxes
incurred in connection with the acquisition of the shares. Any such promissory
note may be subject to forgiveness in whole or in part, at the discretion of the
Plan Administrator, over the participant's period of service.
SPECIAL TAX ELECTION
The Plan Administrator may provide one or more holders of options
or unvested shares with the right to have the Company withhold a portion of the
shares otherwise issuable to such individuals in satisfaction of the tax
liability incurred by such individuals in connection with the exercise of those
options or the vesting of those shares. Alternatively, the Plan Administrator
may allow such individuals to deliver previously acquired shares of Common Stock
in payment of such tax liability.
19
<PAGE> 23
AMENDMENT AND TERMINATION
The Board may amend or modify the Omnibus Plan in any or all
respects whatsoever subject to any required stockholder approval. The Board may
terminate the Omnibus Plan at any time, and the Plan shall terminate upon the
earliest of (i) April 23, 2005, (ii) the date on which all shares available for
issuance under the Plan shall have been issued as fully-vested shares or (iii)
the termination of all outstanding options in connection with a Corporate
Transaction. Upon such Plan termination, all outstanding options and unvested
stock issuances shall continue to have force and effect in accordance with the
provisions of the documents evidencing such options.
STOCK AWARDS
The table below shows, as to each of the Company's Named Executive
Officers and the various indicated individuals and groups, the number of shares
of Common Stock subject to options granted between January 1, 1997 and March 16,
1998 under the Omnibus Plan and the Predecessor Plans together with the weighted
average exercise price payable per share. These include options granted subject
to stockholder approval of this proposal and are included in the new plan
benefits table below.
OPTION TRANSACTIONS
<TABLE>
<CAPTION>
WEIGHTED
NUMBER OF AVERAGE
NAME OPTION SHARES EXERCISE PRICE
- ---- ------------- --------------
<S> <C> <C>
Michael S. Rosen 650,000(1) $2.46875
President and CEO
Robert N. Brey 50,000(2) $2.46875
Vice President, Vaccine Development
Richard Dunning, Director 42,000(1) $2.46875
Steve H. Kanzer, Director 187,000(1) $2.46875
Paul Rubin, Director 42,000(1) $2.46875
H. Laurence Shaw, Director 42,000(1) $2.46875
Andrew Stein, Director 42,000(1) $6.50000
Kenneth Tempero, Director 67,000(1) $2.46875
Steven Thronton, Director 42,000(1) $6.75000
All current executive officers as a group 875,000(3) $2.97321
(4 persons)
All non-employee directors as a group 464,000(1) $3.22117
(7 persons)
All employees, including current officers 77,500(4) $4.16935
who are not executive officers as a group
</TABLE>
(1) These options were granted subject to stockholder approval at the 1998
Annual Meeting.
(2) 33,672 options were granted subject to stockholder approval at the 1998
Annual Meeting.
(3) 858,672 options were granted subject to stockholder approval at the 1998
Annual Meeting.
(4) 47,500 options were granted subject to stockholder approval at the 1998
Annual Meeting.
FEDERAL INCOME TAX CONSEQUENCES
OPTION GRANTS
Options granted under the Omnibus Plan may be either incentive
stock options which satisfy the requirements of Section 422 of the Internal
Revenue Code or non-statutory options which are not intended to meet such
requirements. The Federal income tax treatment for the two types of options
differs as follows:
20
<PAGE> 24
Incentive Options. No taxable income is recognized by the optionee
at the time of the option grant, and no taxable income is generally recognized
at the time the option is exercised. The optionee will, however, recognize
taxable income in the year in which the purchased shares are sold or otherwise
disposed of. For Federal tax purposes, dispositions are divided into two
categories: (i) qualifying and (ii) disqualifying. A qualifying disposition
occurs if the sale or other disposition is made after the optionee has held the
shares for more than two years after the option grant date and more than one
year after the exercise date. If either of these two holding periods is not
satisfied, then a disqualifying disposition will result.
If the optionee makes a disqualifying disposition of the purchased
shares, then the Company will be entitled to an income tax deduction, for the
taxable year in which such disposition occurs, equal to the excess of (i) the
fair market value of such shares on the option exercise date over (ii) the
exercise price paid for the shares. In no other instance will the Company be
allowed a deduction with respect to the optionee's disposition of the purchased
shares.
Non-Statutory Options. No taxable income is recognized by an
optionee upon the grant of a non-statutory option. The optionee will in general
recognize ordinary income, in the year in which the option is exercised, equal
to the excess of the fair market value of the purchased shares on the exercise
date over the exercise price paid for the shares, and the optionee will be
required to satisfy the tax withholding requirements applicable to such income.
If the shares acquired upon exercise of the non-statutory option
are unvested and subject to repurchase by the Company in the event of the
optionee's termination of service prior to vesting in those shares, then the
optionee will not recognize any taxable income at the time of exercise but will
have to report as ordinary income, as and when the Company's repurchase right
lapses, an amount equal to the excess of (i) the fair market value of the shares
on the date the repurchase right lapses over (ii) the exercise price paid for
the shares. The optionee may, however, elect under Section 83(b) of the Internal
Revenue Code to include as ordinary income in the year of exercise of the option
an amount equal to the excess of (i) the fair market value of the purchased
shares on the exercise date over (ii) the exercise price paid for such shares.
If the Section 83(b) election is made, the optionee will not recognize any
additional income as and when the repurchase right lapses.
The Company will be entitled to an income tax deduction equal to
the amount of ordinary income recognized by the optionee with respect to the
exercised non-statutory option. The deduction will in general be allowed for the
taxable year of the Company in which such ordinary income is recognized by the
optionee.
STOCK APPRECIATION RIGHTS
An optionee who is granted a stock appreciation right will
recognize ordinary income in the year of exercise equal to the amount of the
appreciation distribution. The Company will be entitled to an income tax
deduction equal to the appreciation distribution for the taxable year in which
the ordinary income is recognized by the optionee.
ACCOUNTING TREATMENT
Option grants or stock issuances with exercise or issue prices less
than the fair market value of the shares on the grant or issue date will result
in a compensation expense to the Company's earnings equal to the difference
between the exercise or issue price and the fair market value of the shares on
the grant or issue date. Such expense will be accruable by the Company over the
period that the option shares or issued shares are to vest. Option grants or
stock issuances at 100% of fair market value will not result in any charge to
the Company's earnings. Whether or not granted at a discount, the number of
outstanding options may be a factor in determining the Company's earnings per
share on a fully-diluted basis. Under the new FASB release, footnote disclosure
will be required as to the impact the outstanding options under the Omnibus Plan
would have upon the Company's reported earnings were those options appropriately
valued as compensation expense.
21
<PAGE> 25
Should one or more optionees be granted stock appreciation rights
which have no conditions upon exercisability other than a service or employment
requirement, then such rights will result in a compensation expense to the
Company's earnings.
STOCKHOLDER APPROVAL
The affirmative vote of a majority of the outstanding voting shares
of the Company present or represented and entitled to vote at the 1998 Annual
Meeting is required for approval of the Omnibus Plan, as amended and restated.
Should such stockholder approval not be obtained, then the amendment and
restatement of the Omnibus Plan will not be effected and all options issued on
the basis of the share increase subject to this proposal will terminate
unexercised. The Company's Predecessor Plans and the Omnibus Plan as in effect
prior to the amendment and restatement will, however, continue to remain in
effect, and option grants and stock issuances may continue to be made pursuant
to the provisions of those plans until the available reserve of Common Stock
under such plans is issued.
The Board of Directors recommends that the stockholders vote FOR
the approval of the Amended and Restated Omnibus Incentive Plan. The Board
believes that it is in the best interests of the Company to maintain a
comprehensive equity incentive program for the Company which will provide a
meaningful opportunity for officers, employees, non-employee Board members and
consultants to acquire a substantial proprietary interest in the enterprise and
thereby encourage such individuals to remain in the Company's service and more
closely align their interests with those of the stockholders.
NEW PLAN BENEFITS
The table below shows, as to each of the Company's Named Executive
Officers and the various indicated individuals and groups, the number of shares
of Common Stock subject to options granted subject to approval of this Proposal
through March 16, 1998 under the Omnibus Plan and the Predecessor Plans together
with the weighted average exercise price payable per share.
NEW PLAN BENEFITS
<TABLE>
<CAPTION>
WEIGHTED
NUMBER OF AVERAGE
NAME OPTION SHARES EXERCISE PRICE
---- ------------- --------------
<S> <C> <C>
Michael S. Rosen
President and CEO 650,000 $2.46875
Robert N. Brey
Vice President, Vaccine Development 33,672 $2.46875
Richard Dunning, Director 42,000 $2.46875
Steve H. Kanzer, Director 187,000 $2.46875
Paul Rubin, Director 42,000 $2.46875
H. Laurence Shaw, Director 42,000 $2.46875
Andrew Stein, Director 42,000 $6.50000
Kenneth Tempero, Director 67,000 $2.46875
Steven Thronton, Director 42,000 $6.75000
All current executive officers as a group
(4 persons) 858,672 $2.97321
All non-employee directors as a group
(7 persons) 464,000 $3.22117
All employees, including current officers who are not
executive officers as a group 47,500 $5.24342
</TABLE>
22
<PAGE> 26
PROPOSAL 4
NAME CHANGE
The Company's stockholders are being asked to approve an amendment
(the "Certificate of Amendment") to the Company's Amended and Restated
Certificate of Incorporation which will have effect of changing the Company's
name from "Endorex Corp." to "Endorex Corporation". The Company has been
transacting business for some time under the name "Endorex Corporation" and,
therefore, would like to change the legal name of the Company in accordance with
how it has been operating.
The affirmative vote of a majority of a majority of the outstanding
shares of the Common Stock present or represented and entitled to vote at the
1998 Annual Meeting is required for approval of the Certificate of Amendment.
STOCKHOLDER PROPOSALS
In accordance with regulations issued by the Securities and
Exchange Commission, stockholder proposals intended for presentation at the 1999
Annual Meeting of Stockholders must be received by the Secretary of the Company
no later than January 1, 1999 if such proposals are to be considered for
inclusion in the Company's Proxy Statement.
OTHER MATTERS
Management knows of no matters that are to be presented for action
at the meeting other than those set forth above. If any other matters properly
come before the meeting, the persons named in the enclosed form of proxy will
vote the shares represented by proxies in accordance with their best judgment on
such matters.
Proxies will be solicited by mail and may also be solicited in
person or by telephone by some regular employees of the Company. The Company may
also consider the engagement of a proxy solicitation firm. Costs of the
solicitation will be borne by the Company.
By Order of the Board of Directors
Michael S. Rosen
Chief Executive Officer and Secretary
Lake Bluff, Illinois
April 10, 1998
23
<PAGE> 27
PROXY CARD
ENDOREX CORPORATION
900 NORTH SHORE DRIVE - LAKE BLUFF, IL 60044
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
MAY 13, 1998
The annual meeting of stockholders (the "Annual Meeting") of Endorex
Corp. (the "Company") will be held at the offices of Brobeck Phleger & Harrison
LLP, 1633 Broadway, 47th Floor, New York, New York 10019, telephone number
(212) 581-1600 on May 13, 1998, at 10:30 A.M. (eastern daylight time) for the
following purposes, each as more fully described herein:
Only stockholders of record at the close of business on March 27, 1998
are entitled to notice of and to vote at the Annual Meeting. A list of
stockholders eligible to vote at the meeting will be available for inspection
at the meeting and for a period of ten days prior to the meeting during regular
business hours at the corporate headquarters at the address above.
Whether or not you expect to attend the Annual Meeting, your proxy vote
is important. To assure your representation at the Annual Meeting, please sign
and date the enclosed proxy card and return it promptly in the enclosed
envelope, which requires no additional postage if mailed in the United States.
(1) To elect eight directors to serve until the next Annual Meeting or
until their respective successors shall have been duly elected and
qualified;
Nominees:
Michael S. Rosen
Richard Dunning
Steve H. Kanzer
Paul D. Rubin
H. Laurence Shaw
Andrew Stein
Kenneth Tempero
Steven Thornton
(2) To ratify the appointment of Coopers & Lybrand L.L.P. as
independent public accountants for the year ending December 31,
1998;
(3) To approve the Amended and Restated 1995 Omnibus Incentive Plan;
(4) To approve name change of the Company from "Endorex Corp." to
"Endorex Corporation"; and
(5) To transact such other business as may properly come before the
Annual Meeting.
